Anupma Lal, MD
Internal Medicine · Fort Wayne, INNPI 1487600599
Payments from drug & device makers
Across 185 payments — averaging $16.45 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AbbVie$525
- AstraZeneca$299
- Bayer$277
- Lilly USA, LLC$223
- Novartis$204
- Novo Nordisk$171
- plus $1K from 27 others
What the payments were for
- Food & beverage$3,043100%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AbbVie | 39 | $525 |
| AstraZeneca | 16 | $299 |
| Bayer | 24 | $277 |
| Lilly USA, LLC | 12 | $223 |
| Novartis | 8 | $204 |
| Novo Nordisk | 11 | $171 |
| Abbott | 6 | $130 |
| GSK | 6 | $104 |
| Amgen(2 entities) | 7 | $98 |
| Axsome Therapeutics, Inc. | 4 | $87 |
| Pfizer | 4 | $85 |
| Boehringer Ingelheim | 5 | $81 |
| Astellas Pharma US Inc | 3 | $59 |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLC | 4 | $58 |
| Otsuka America Pharmaceutical, Inc. | 3 | $58 |
| Exact Sciences | 3 | $57 |
| Dexcom, Inc. | 3 | $56 |
| ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.) | 3 | $56 |
| Lexicon Pharmaceuticals, Inc. | 3 | $51 |
| Xeris Pharmaceuticals, Inc. | 3 | $47 |
| Sumitomo Pharma America, Inc. | 2 | $45 |
| Corcept Therapeutics | 2 | $45 |
| Merck | 2 | $33 |
| Shield Therapeutics Inc | 2 | $33 |
| Johnson & Johnson | 2 | $27 |
| Amneal Pharmaceuticals LLC | 1 | $21 |
| Phathom Pharmaceuticals, Inc. | 1 | $19 |
| Vanda Pharmaceuticals Inc. | 1 | $19 |
| Idorsia Pharmaceuticals US Inc | 1 | $17 |
| Lifescan, Inc. | 1 | $16 |
| Jazz Pharmaceuticals Inc. | 1 | $14 |
| Kowa Pharmaceuticals America, Inc. | 1 | $14 |
| Alfasigma USA, Inc. | 1 | $11 |
How this compares
$3,043 in reported general payments places this provider in the 85th percentile of 1,747 internal medicine providers in Indiana.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| JardianceEmpagliflozin | 158 | $174,742 |
| OzempicSemaglutide | 102 | $153,104 |
| MounjaroTirzepatide | 79 | $105,980 |
| JanuviaSitagliptin Phosphate | 57 | $69,942 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 70 | $66,293 |
| Tresiba Flextouch U-200Insulin Degludec | 19 | $47,373 |
| EliquisApixaban | 42 | $43,978 |
| KerendiaFinerenone | 48 | $41,623 |
| Toujeo SolostarInsulin Glargine,hum.Rec.Anlog | 22 | $40,385 |
| ProliaDenosumab | 15 | $26,191 |
| MyrbetriqMirabegron | 17 | $19,347 |
| Breo ElliptaFluticasone/Vilanterol | 34 | $14,957 |
| VascepaIcosapent Ethyl | 18 | $11,610 |
| Spiriva RespimatTiotropium Bromide | 12 | $8,185 |
| Duloxetine Hcl | 139 | $6,014 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Boehringer IngelheimJardiance, Spiriva Respimat | $81 | $182,927170 claims |
| Novo NordiskOzempic | $171 | $153,104102 claims |
| Lilly USA, LLCMounjaro | $223 | $105,98079 claims |
| GSKTrelegy Ellipta, Breo Ellipta, Arnuity Ellipta | $104 | $86,297124 claims |
| MerckJanuvia | $33 | $69,94257 claims |
| PfizerEliquis | $85 | $43,97842 claims |
| BayerKerendia | $277 | $41,62348 claims |
| AmgenProlia | $98 | $26,19115 claims |
| Astellas Pharma US IncMyrbetriq | $59 | $19,34717 claims |
| Amneal Pharmaceuticals LLCLevothyroxine Sodium | $21 | $4,907514 claims |
| AbbVieSynthroid | $525 | $3,83049 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 1,747 internal medicine providers in Indiana.
Other internal medicine in Fort Wayne
- David IloFort Wayne$86K
- Anuradha KolliparaFort Wayne$30K
- Sumona KabirFort Wayne$28K
- Robert BuynakValparaiso$24.2M
- Mohammed AllawNewburgh$3.6M
- Raj VuppalanchiIndianapolis$3.4M
- Phillip TothIndianapolis$3.2M
- George CornettFranklin$1.3M
- Ajita NarayanLafayette$951K
- Abhinav SinghGreenwood$738K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.